Condition: Esophageal Cancer · Sponsor: The First Affiliated Hospital of Zhengzhou University
The purpose of this study is to observe and evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and cisplatin as perioperative treatment of advanced esophageal squamous cell.
This description comes directly from the study's public registry record.
Song Zhao · 13673665008 · zhaosong@zzu.cn
Yu Qi · 13803892392 · qiyu@zzu.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Zhengzhou University | Zhengzhou, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05182944